When trial results come in for a company in the health care space, it's often do or die, make or break. In this video, Motley Fool health care analyst David Williamson takes us through three such results just in, and what's happened with shares as a result. Tranzyme (NASDAQ:TZYM) was today's biggest loser, with shares down a devastating 75% after results came in that its drug TZP-102 was no better than a placebo in helping gastroparesis patients. AcelRX (NASDAQ:ACRX), on the other hand, was up after excellent results with its drug sufentanil nanotab pca in comparison with intravenous morphine for treating post-operative pain, and Threshold Pharmaceuticals (NASDAQ:THLD) experienced a jump up that has now settled back down, after some initial excitement about the results of its drug TH302 applied to maintenance therapy for soft-tissue sarcoma.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.